Advanced Search
CHEN Y L, WANG P S, CHEN Y L, et al. Research progress of serine hydroxymethyltransferase inhibitors in tumor treatment[J]. Chin J Clin Med, 2025, 32(1): 125-134. DOI: 10.12025/j.issn.1008-6358.2025.20241030
Citation: CHEN Y L, WANG P S, CHEN Y L, et al. Research progress of serine hydroxymethyltransferase inhibitors in tumor treatment[J]. Chin J Clin Med, 2025, 32(1): 125-134. DOI: 10.12025/j.issn.1008-6358.2025.20241030

Research progress of serine hydroxymethyltransferase inhibitors in tumor treatment

  • Tumor is the result of long-term and unlimited proliferation of cells. Tumor cells adjust various metabolic fluxes to meet increased bioenergy and biosynthetic requirements. Serine is one of the eight non-essential amino acids in the human body. It plays an important role in a variety of physiological activities and can provide one carbon unit, glycine, etc. for cell proliferation. Serine hydroxymethyltransferase (SHMT) is a key enzyme that catalyzes the conversion of glycine and serine. It is highly expressed in a variety of tumors and is a potential target for anti-tumor drugs. This article focuses on the potential of SHMT as a new target for cancer treatment and the preliminary application of its inhibitors in preclinical studies of tumors, providing reference for the development of new targeted drugs for tumors.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return